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Abstract
During the last decades the description of autoinflammatory syndromes induced great interest among the scienti-
fic community. Mainly rheumatologists, immunologists and pediatricians are involved in the discovery of etiopatho-
genesis of these syndromes and in the recognition of affected patients. In this paper we will discuss the most
important clues of monogenic and non-genetic inflammatory syndromes to help pediatricians in the diagnosis and
treatment of these diseases.
Introduction
The first time that a periodic disease was mentioned in
the medical literature was in 1802 when Heberden
described a condition characterized by recurrent abdom-
inal pain, thoracic pain and painful extremities. Later
several syndromes with recurrent episodes of fever and
inflammatory symptoms were recognized, some of
which with Mendelian inheritance pattern [1,2]. The
term hereditary recurrent fever syndrome was associated
to this group of syndromes; attacks begin early, usually
before 10 years of age and recur with irregular intervals
of time [3]. During the past decade, the term “autoin-
flammatory syndromes” was introduced by Kastner to
include all those disorders that did not fit into classical
groups of immune-mediated diseases, and characterized
by recurrent fever associated with rheumatologic symp-
toms involving joints, skin, muscles, and eyes. The main
difference with autoimmune diseases is that neither
autoantigens nor autoantibodies are involved. Autoin-
flammatory syndromes are associated to a disregulation
of the innate immune response with subsequent epi-
sodes of acute spontaneous inflammation [3]. This con-
cept was initially assigned to the hereditary recurrent
fevers but now is expanding to a broad number of
disorders.
Thanks to the advanced techniques in genetics, to
date many genes have been recognized in the pathogen-
esis of periodic syndromes like familial Mediterranean
fever (FMF), hyper IgD syndrome (HIDS), tumor necro-
sis factor receptor associated autoinflammatory syn-
drome (TRAPS), cryopyrin associated periodic
syndromes (CAPS), Blau syndrome and pyogenic sterile
arthritis pyoderma gangrenosum and acne syndrome
(PAPA). Some of these genes are still available for the
molecular diagnosis, especially in patients with familial
recurrence or with highly suggestive clues. Gattorno and
collegues identified major clinical clues to predict the
possibility of a genetic alteration in a suspected autoin-
flammatory syndrome. Early onset, family history of per-
iodic fever, thoracic and abdominal pain, diarrhea and
oral aphtous ulcers represent the most relevant clues to
predict the possibility of a positive genetic test. The
authors also proposed a flow chart based on the clinical
profile of patients with suspected autoinflammatory syn-
dromes with the purpose to identify patients with effec-
tive need of a genetic analysis. Thanks to this method,
the number of genetic tests and relative costs have been
significantly reduced [4].
To date few periodic syndromes remain of unknown
origin like PFAPA syndrome (periodic fever, aphtous
stomatitis, pharyngitis and adenitis), characterized by
periodic fever attacks with early onset, of non-infective
origin, with benign prognosis in the absence of familial
inheritance [5] and Majeed syndrome, characterized by
recurrent multifocal osteomyelitis (CRMO), congenital
dyserithropoietic anemia, and neutrophilic dermatosis.
Epidemiological data about inflammatory diseases are
poor; generally they are quite rare diseases. No gender
prevalence has been described; only some reports
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recorded mild predominance in males for FMF [6]. The
prevalence of other autoinflammatory syndromes is
lower than FMF, but not yet quantified.
There are not specific and standardized therapies for
the acute attacks of fever. On the other way long term
treatment is available, effective in reducing the number
and intensity of attacks and preventing severe complica-
tions like amyloidosis.
Acute attacks, especially in FMF, usually need a com-
bination of drugs like non steroidal anti-inflammatory
drugs (NSAIDs) and analgetics.
The proven effectiveness of anti IL-1 drugs in many
autoinflammatory disorders made these drugs as first
line choice in long-term treatment.
Familial Mediterranean fever (FMF)
FMF, first described in 1945 by Siegal, is the most com-
mon autoinflammatory syndrome. It is an autosomal
recessive inherited condition, prevalent among people of
Mediterranean descent (Arabs, Turks, Armenians, non-
Ashkenazi and Sephardic Jews) but may affect any eth-
nic group [7]; its prevalence is high among Sephardic
Jews (100-400 every 100000 inhabitants) and quite low
in west Europeans (2.5 per 100000) [3].
FMF is caused by mutations in the MEFV (MEditerra-
nean FeVer) gene, located on the short arm of chromo-
some 16 (16p13.3). At least 100 disease-linked
mutations in the MEFV gene have been described, the
most being clustered in the 10th exon of this gene. The
MEFV gene encodes for a protein of 781 aminoacids
known as pyrin (or marenostrin). Pyrin is primarily
expressed in neutrophils, eosinophils, monocytes, den-
dritic cells and fibroblasts. Wild-type pyrin suppresses
inflammasome-mediated IL-1b production. Furthermore,
wild-type pyrin plays an antiapoptotic role through inhi-
bition of NF-kB nuclear trascription factor [8]. The
most commonly reported mutations of MEFV gene are
M694V, M680I and V726A. The presence of M694V
mutation has been associated with more severe disease
course and in particular with the development of amy-
loidosis [9].
FMF is clinically characterized by recurrent attacks of
high spiking fever with associated serositis that usually
last 1-3 days and subside spontaneously. Frequency of
attacks is highly variable and asymptomatic periods last-
ing a few years have been reported [3]. Triggers may
include stress, menstrual cycle, exercise and subclinical
infections [7]. Recurrent fever may be the only manifes-
tation in childhood [10]. Abdominal pain is present in
95% of cases and is associated with board-like rigidity of
abdominal muscles, rebound tenderness, constipation or
diarrhea [7,10]. Multiple air-fluid levels may be present
on radiologic examination, leading to the suspicion of
an acute abdomen [6]; the severity of the peritoneal
episodes may mimic acute appendicitis and many
patients have undergone appendicectomy [11]. Chest
pain because of pleuric or pericardial involvement
occurs in 33-53% of subjects. Patients with pleural invol-
vement may have shallow breathing and dyspnoea. Mus-
culo-skeletal involvement is frequent and characterized
by myalgia, arthritis and/or arthralgia. Arthritis occurs
in about 25 to 41% of cases [10]. It may be divided into
three groups: 1) asymmetrical non destructive arthritis,
in which one or two joints are swollen (most frequent
by knees, ankles, and wrists) 2) chronic destructive
arthritis, including sacroiliitis, 3) migratory polyarthritis.
Splenomegaly and scrotal pain may be present in pre-
pubertal children during attacks. Thirty per cent of
patients experience painful erysipela-like skin lesions
usually on the distal extremities. A number of other dif-
ferent cutaneous manifestations such as Henoch-Schön-
lein purpura and polyarteritis nodosa can also occur
during fever episodes [2,10,11].
Laboratory investigations during acute attacks are non-
specific: leukocyte count, sedimentation rate and C-reac-
tive protein (CRP) are often elevated during flares [2].
Amyloidosis is the most significant complication of
FMF and may result in a progressive accumulation of
serum amyloid A protein (SAA) mainly in the kidney.
The most common clinical manifestation of amyloidosis
is the development of proteinuria that may lead to renal
failure. Patients are frequently normotensive and do not
present hematuria. Before the advent of colchicine, the
prevalence of amyloidosis among FMF patients was high
ranging from 60% to 80% [12]. Renal involvement is
usually observed after a variable time from disease
onset. In few patients (less than 1%), renal amyloidosis
may represent the first manifestation of the disease [6].
Acute attacks of FMF usually respond to a combina-
tion of non-steroidal anti-inflammatory drugs (NSAIDs)
and analgesics. Colchicine is the treatment of choice for
FMF. It greatly reduces the frequency and intensity of
clinical attacks and prevents the development of renal
amyloidosis. In adults the dose is 1 mg/day. In children
the starting dose should be ≤0.5 mg/day for children
below 5 years of age, 1 mg/day for children 5-10 years,
and 1.5 mg/day for children above 10 years. Dosage can
be increased in a stepwise fashion up to a maximum of
2 mg/day [2]. Only 5% of patients are non responders.
Lack of response to colchicine is often caused by poor
adherence to treatment [3].
Biologic treatments (anti TNF-a, anti IL-1 b) have
been proposed in non responsive patients, although
their efficacy has not been proved [2,10,13].
Hyper IgD syndrome (HIDS)
Hyper IgD syndrome is an autosomal recessive disease
characterized by recurrent fever attacks, preceded by
De Sanctis et al. Italian Journal of Pediatrics 2010, 36:57
http://www.ijponline.net/content/36/1/57
Page 2 of 7
chills and malaise; it was identified in 1984 in 6 patients
with a history of recurrent fever and elevation of serum
IgD. This syndrome seems to be more prevalent in Cau-
casians, especially in western Europeans [14]. Since it
was first described, about 180 cases have been reported,
and the majority of them living in France and Nether-
land [3,15].
HIDS is linked to mutations in the MVK gene (locus
12q24) which encodes the mevalonate kinase (MVK)
[16], mainly expressed in peroxysomes. This enzyme is
responsible of converting mevalonic acid into 5-phos-
phomevalonic acid which is a fundamental precursor of
sterols (cholesterol, steroid hormones, vitamin D, bile
salts) and isoprenoids. In HIDS patients residual enzyme
activity of MVK is reduced to 1-8%, so the metabolic
pathway of steroids synthesis induces lower levels of
serum cholesterol, higher urinary excretion of mevalonic
acid and higher activity of hydroxy-metil-coA reductase
(HMG-coA) for the shunt of metabolic precursors
towards the synthesis of pro-inflammatory isoprenoids
[17]. This metabolic shunt could explain the efficacy of
statines in reducing symptoms of HIDS, thanks to the
anti-inflammatory effect of competiting inhibition of
HMG-coA reductase [18].
Acute attacks can be triggered by physical stress or
vaccination, can last 3 to 7 days and recur after 4 to 6
weeks. However a great variability can be observed as in
many other periodic fever syndromes. Ninety per cent
of HIDS patients experience first symptoms in the first
year of life. Fever is usually associated with painful neck
lymphadenopathy, abdominal pain, vomiting and diar-
rhea. About 50% of affected patients show aphtous oral
or genital ulcers. Hepatosplenomegaly, maculopapular
skin rash, nodules, urticarial or measle-like rash, arthral-
gias and non erosive arthritis of large joints can be pre-
sent. Polyarticular arthritis is often remitting [2,3,11,19].
In the past years, high levels of IgD (> 100 UI/ml)
during fever attacks was considered to be the main fea-
ture of HIDS, although their specificity is quite low:
high levels of IgD can also be found in FMF or in
TRAPS patients [20]. In some cases high levels of serum
IgA and urinary mevalonic acid can be found during
fever. Anyway urinary measure of mevalonic acid
requires specialized laboratories, thus it is difficult to
perform as a screening test. The decision to undergo a
genetic test for HIDS in a child with periodic fever syn-
drome should be guided by clinical suspicion [2]. About
25% of patients with typical HIDS attacks and high
serum IgD levels do not show any mutation of MVK
gene [21].
During acute attacks the main treatment option are
steroids (mainly prednisone in a single dose of 1 mg/
day) [2]. Long term treatment in HIDS patients is quite
controversial; in the literature there are only anecdotal
cases of response to steroids, intravenous immunoglobu-
lines, colchicine or cyclosporine A [14,22]. Thalidomide
use has not proven to be efficacious while simvastatine
use is quite encouraging in adult patients [14,23]. Dur-
ing the last years many studies have been reported on
biologic drugs. Etanercept has been particularly studied
for the pediatric age with controversial results [24-27].
In 2005 Bodar and coworkers showed variable response
to etanercept in HIDS patients but in the same time
anakinra has proven to be more effective in reducing
the duration of symptoms [27]. Recent findings on bio-
logics have shown that anakinra is the most effective in
the control of fever attacks: new perspectives for HIDS
treatment are now under judgement [28].
TNF Receptor Associated Periodic Syndrome (TRAPS)
TRAPS is an auto- inflammatory multiorgan disease
characterized by alternation of active and remission
phases, which may be complicated with organ injury, in
particular amyloidosis [29].
TRAPS, also known as Hybernian fever, was first
described in 1982; it seems to be homogeneously dis-
tributed among different ethnic groups [11]; more than
200 cases are recorded in the international medical lit-
erature [3].
TRAPS has autosomal dominant inheritance; it is due
to the mutations of TNFRSF1A gene, located on the
short arm of chromosome 12. The gene encodes for the
TNF membrane receptor (TNFR1); it consists of an
extracellular domain that binds circulating TNF-a, a
trans-membrane domain and an intracellular portion
that transduce the signal inside the cell [30]. The wild-
type TNFRSF1A protein interacts with circulating TNF-
a and disconnects from the cell surface to neutralize the
effect of the TNF-a; the mutant TNFRSF1A protein is
unable to disconnect from the cell membrane, inducing
continuous pro-inflammatory signal transmission by
TNF-a [31].
TRAPS patients have episodes of recurrent fever asso-
ciated with myalgia, migrant skin lesions, red, swollen,
painful speckled localized to the trunk and extremities.
Febrile attacks continue approximately two days but can
last for weeks [2]. It is also common to find chest and
abdominal pain, arthralgia of large joints, testicular pain,
lymphadenopathy, headache, ocular involvement with
periorbital edema and rarely aseptic conjunctivitis, uvei-
tis or episcleritis [32].
TRAPS onset in pediatric age can be confused with
juvenile idiopathic arthritis; it may also coexist with
multiple sclerosis, panniculitis and vasculitis [33].
Acute episodes of TRAPS are characterized by a sig-
nificant increase in acute phase reactants, neutrophilia
and various degrees of hypochromic anemia [2]. The
soluble TNF receptor levels are low both during attacks
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and during intercritical period [33]. Molecular studies
showed about 80 variants of the TNFRSF1A gene, and
about 64 of these have been identified in patients with a
typical phenotype of TRAPS. The most common muta-
tions are the R92Q and P46L, which show low pene-
trance, as demonstrated by their presence in
asymptomatic relatives of TRAPS patients [34]. Further-
more, studies of genotype-phenotype correlation, even
in the pediatric population [35], showed that mutations
causing substitution of a cysteine residue are associated
with a severe course of the disease and with increased
possibility to develop renal amyloidosis.
TRAPS febrile attacks usually respond to steroids, but
due to the possible long duration of episodes and the
tendency to a chronic course, patients often become
steroid-dependent [2]. The use of immunosuppressive
drugs has proved ineffective in patients with TRAPS in
reducing frequency and intensity of inflammatory epi-
sodes and in preventing the development of amyloidosis
[33]. After the discovery of the underlying genetic
defect, anti-TNF drugs, particularly etanercept, assumed
a relevant role in the therapy of these disease [36]. The
use of etanercept has proven to be effective in the con-
trol the symptoms and in some cases also in the
improvement of nephrotic syndrome secondary to renal
amyloidosis [32]. However, in some patients anti-TNF
drugs, in particular infliximab, have been shown not
fully able to control the inflammation [37]. On the con-
trary the use of anakinra seems to be an effective thera-
peutic strategy [38].
Cryopyrinopaties (CAPS)
Cryopyrin-associated periodic syndromes encompass a
spectrum of diseases characterized by recurrent inflam-
mation and complications like renal amyloidosis, loss in
sight, deafness and articular damage [31]. The term
“cryopyrinopathies” clusters three syndromes all charac-
terized by the mutation of CIAS1 gene:
• Familial Cold Autoinflammatory Syndrome (FCAS),
first described in 1940;
• Muckle-Wells Syndrome (MWS), first described in
1962;
• Chronic Infantile Neurologic Cutaneous Articular
Syndrome - Neonatal Onset Multisystem Inflammatory
Syndrome (CINCA/NOMID), first described in 1981 by
Prieur and Griscelli [2].
The CIAS1 gene is located on the long harm of chro-
mosome 1 (1q44) and encodes for a protein called cryo-
pyrin, which is involved in the formation of
“inflammasome”, a complex of protein that induced the
activation of caspase 1 and the secretion of IL-1
[1,39,40].
FCAS is the mildest form. Its clinical features are fever
spikes of short duration (typically less than 24hours),
induced by exposure to cold and associated with profuse
sweating, drowsiness, headache and nausea, conjunctivi-
tis, and arthralgia [2]. FCAS attacks usually begin within
the first few months of life [11].
MWS presents variable age of onset and is character-
ized by recurrent episodes of fever associated with urti-
caria: fever, usually less than 38°C, resolves
spontaneously between 12 and 36 hours and is asso-
ciated with the same symptoms of FCAS although it is
never triggered by the exposure to low temperatures.
MWS may be complicated by progressive hearing loss
and amyloidosis even in childhood [2,31].
The CINCA/NOMID represents the most severe phe-
notype; it occurs mostly in the neonatal period or in
early childhood, with an urticarial rash. One third of
children have a typical “facies” including frontal promi-
nence, saddle nose and facial hypoplasia; other skeletal
features are abnormal bone and cartilage growth, espe-
cially in the distal extremities of hands, feet, knees and
particularly of the patella (giant kneecap). Polyarticular
chronic inflammation is often erosive and deforming [2].
This syndrome also includes the possible involvement of
the central nervous system (aseptic chronic meningitis,
progressive hearing loss, chronic headaches, mental
retardation, epilepsy) and of eyes with anterior uveitis,
papillitis and optic nerve atrophy [11,31,32].
The pathogenetic mechanisms of these diseases have
allowed to identify anti IL-1 drugs as the most appropri-
ate therapy. Anti IL-1 drugs, in particular anakinra
(1 mg/Kg/day subcutaneously) are life saving drugs in
patients with CAPS that usually respond to treatment
within the first 24 hours [41]. Clinical studies have
shown significant improvement in the clinical symptoms
of CAPS including rash, headaches, fevers, joint pain
and improvement in inflammatory markers with remis-
sion even in 60% of patients with CINCA/NOMID [42].
However, it may be difficult to achieve a complete reso-
lution of neurologic involvement and high doses are
often required [42,43]. Recent introduction of long act-
ing IL-1inhibitors rilonacept and canakinumab also
showed efficacy in patients with CAPS; both drugs were
recently approved by Food and Drug Administration
(FDA) for the treatment of CAPS [44,45].
Blau syndrome
Blau syndrome was first described in 1985 as an autoso-
mal-dominant autoinflammatory disease, familial or
sporadic; it is caused by mutation in the NACHT
domain of CARD15 (NOD2) (16q12.1-13) [2]. Disease
onset is usually observed during the first years of life. It
is characterized by non-caseating granulomatous lesions
affecting joints (symmetric polyarthritis), skin and eyes,
particularly the uveal tract. About 50% of patients with
uveitis develop cataract, and one third may develop
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secondary glaucoma. Patients are treated with oral ster-
oids and immunosuppressive drugs (methotrexate or
cyclosporine A). Recently biologics are also used, espe-
cially anti-TNF (infliximab) and anti-IL1 drugs [2].
PAPA syndrome
Pyogenic sterile arthritis, pyoderma gangrenosum and
acne syndrome is caused by mutations in the CD2BP1
or PSTPIP1 (15q22-24) gene [2].
Arthritis onsets in early childhood and has been
proved to be responsive to corticosteroids. It is destruc-
tive, primarily involving non-axial joints such as knees,
elbows and ankles. Prominent cutaneous findings
include cystic acne and ulcerative skin lesions, usually of
lower extremities. Radiological examinations show
articular lesions and signs of micrognathia and cervical
ankylosis [46,47]. Cultures of the skin and joints of
these patients are sterile with a neutrophilic infiltrate
[46].
PAPA syndrome shows good response to oral gluco-
corticoids and biologics, particularly in steroid-resistant
patient, with a dramatic improvement of cutaneous
lesions [2].
Majeed’s syndrome: Chronic Recurrent Multifocal
Osteomyelitis (CRMO)
Majeed’s syndrome or CRMO is an auto-inflammatory
osteopathy caused by mutations in LPIN2 gene
(18p11.31) [2]. Symptoms begin in early childhood and
are characterized by fever, bone lesions, pain, congenital
dyserythropoietic anemia and dermatologic manifesta-
tions (psoriasis, palmoplantar pustulosis, acne).
The diagnosis of CRMO is based on the following
critera [48]:
1. ≥2 typical bony lesions (osteolysis with surround-
ing sclerosis on conventional radiographs);
2. duration ≥6 months;
3. typical histologic features on bone biopsy;
4. age < 18 years at diagnosis.
Nonsteroidal antiinflammatory drugs and oral steroids
are useful in the control of symptoms while splenectomy
and blood transfusions have proven to be effective for
controlling hematological manifestations [2].
PFAPA syndrome
The acronym PFAPA is derived from the classical asso-
ciation of fever with pharyngitis, cervical lymphadenopa-
thy and aphthous stomatitis. The disease was first
described by Marshal in 1987; it usually develops before
5 years of age, with no evident correlations to ethnicity,
geographical distribution or gender [5,49]. To date, no
genetic defect has been associated to this syndrome.
PFAPA is characterized by fever spikes (body tempera-
ture of 38.5-41°C) that recur regularly every 2-6 weeks
and last 3-6 days [2]. The affected child has a disease-
free interval of about 3-5 weeks (albeit with great varia-
bility), and overall shows good general condition. The
aphthous lesions observed in PFAPA are generally one
to five, small and not keratinized. They are localized in
the labial gingiva and are rapidly self-remitting [2,49].
Cervical lymphnode are enlarged and tender. In some
cases pharyngitis is associated with follicular exudative
tonsillitis with negative cultural examination for group
A streptococcus and in the absence of signs of upper
respiratory infections.
The child with PFAPA can also present headache,
general malaise, arthritis, gastrointestinal disorders (par-
ticularly nausea and vomiting), splenomegaly in contrast
to a normal somatic growth and normal development
[49].
There are not specific diagnostic tests for PFAPA, so
the diagnosis is based on clinical evaluation and exclu-
sion of other causes. Laboratory testings may reveal
mild leukocytosis and elevated erythrocytes sedimenta-
tion rate only during febrile episodes. Besides, mild ele-
vations in IgA, IgD and IgM are described in some
patients [50]. In the absence of clinical clues suggesting
for an hereditary syndrome, there is no need of genetic
testing. Only in patients with high diagnostic score the
option of genetic analysis should be considered [4].
Treatment of PFAPA is empirical, as the underlying
cause is unknown. The most effective treatment
reported to date is prednisone or prednisolone at the
dose of 1-2 mg/Kg/day at the onset of fever [50]. Cime-
tidine has been associated with resolution of the febrile
episodes [51,52] although the mechanism of action of
this drug in PFAPA has not been determined. Probably
the action of cimetidine is linked to the inhibition of T
suppressor cells by blocking histamine type 2 receptors
[50]. Some patients should be considered for tonsillect-
omy and adenoidectomy if they do not respond to medi-
cal management [53,54].
However, the lack of controlled trials should lead to
caution in interpreting the apparently successful treat-
ment of PFAPA by cimetidine or tonsillectomy.
Conclusions
In children with a suspicion of a periodic fever syn-
drome, an accurate clinical history and a physical exami-
nation remain the first diagnostic tools. In many cases
the diagnosis may not be immediate; long term follow
up is seldom of primary importance to clarify the dis-
ease course and to guide in the diagnostic process. Dif-
ferential diagnosis includes infectious diseases,
malignancies and organ-specific inflammatory syn-
dromes. Only in the absence of other conditions, an
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autoinflammatory syndrome should be considered. The
genetic testing to date has not replaced clinical diagno-
sis; it should be performed only in highly suggestive
cases as discussed before. Furthermore only 50% of
affected patients have positive genetic tests, suggesting
that many genetic loci are still unknown. In the future
genome wide association studies may help in the recog-
nition of candidate genes. Future understandings may
also change therapeutic perspectives, allowing targeted
drugs mostly for those syndromes that today are only
empirically treated.
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